NCT05129969Recruiting
Registry Platform Ovarian and Endometrial Cancer
SMARAGD - Clinical Research Platform on Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancer Treatment and Outcomes
Source: ClinicalTrials.gov · Last updated 28 Jan 2026
Brief summary (registry, in English)
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced or metastatic ovarian cancer (OC) or advanced or metastatic endometrial cancer (EC) in Germany.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1975 (estimated)
- First submitted
- 10 Nov 2021
- Start date
- 25 Nov 2021
- Primary completion date
- Dec 2030
- Lead sponsor
- iOMEDICO AG
- Diseases
- Endometrial cancer, Ovarian cancer
- NCT number
- NCT05129969
What you commit to
- Study type: Observational
- Planned participants: 1975
- From 25 Nov 2021 to the primary completion date, Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- newly diagnosed early-stage OC (FIGO stage I-IIa)
- Low grade mOC OR
- Early-stage EC (FIGO stage I-II)
Who the study is looking for
- Confirmed high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer):
- patients with FIGO stage IIb-IV OC who are starting systemic treatment or
- patients with recurrent/relapsed disease, who received any previous systemic anti-tumor treatment and who are now starting systemic treatment for recurrent/relapsed disease.
- Locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy.
- Signed and dated informed consent (IC):
- Patients participating in PRO module: IC before first therapy cycle
- Patients not participating in PRO module: IC no later than six weeks after start of first therapy cycle
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Multiple sites all over germany Coordinator of this site? Confirm its status | Multiple Locations | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.